Related stories
Pfizer Reports Q3 Revenue of $16.6 Billion, Raises 2026 Guidance
Pfizer reported third-quarter 2026 revenue of $16.6 billion, relatively flat year over year operationally, and adjusted diluted EPS of $0.87. It raised full-year revenue guidance t
M impact | EQUITY | Nov 03, 2026, 01:22 PM UTC
SBI Estimates Rs 19,500 Crore Post-Tax Impact From ECL Framework
State Bank of India has put its expected credit loss models in place, Chairman C S Setty said. The bank will absorb the estimated impact through a phased transition.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
CACI Wins Five-Year, $108 Million U.S. Air Force Contract
CACI said it was awarded a five-year, $108 million contract by the U.S. Air Force to advance financial transparency, operational efficiency and mission readiness.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
Rankin Acquires 41,350 Shares Outside the Marketplace
Rankin acquired 41,350 shares at SEK 235.15 on Nov. 3, 2026, outside the marketplace.
M impact | EQUITY | Nov 03, 2026, 01:16 PM UTC
Petrobras shares fall more than 3% in early trading
M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC
Teva Q3 Revenue Falls 2% to $4.4 Billion, Raises 2026 Brand Outlook
Teva reported third-quarter 2026 revenue of $4.395 billion, down 2% year over year. Gross margin was 55.5%, net income attributable to Teva was $233 million and adjusted diluted EP
M impact | EQUITY | Nov 03, 2026, 01:15 PM UTC